Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Pancreatic cancer pain is a significant clinical challenge.
• Oxycodone (OX) has shown potential advantages over morphine (MO) in visceral pain models.
• Previous research suggests OX may offer benefits in managing cancer pain.

Purpose of the Study:

• To investigate the efficacy and dose escalation of oxycodone (OX) compared to morphine (MO) in patients with pancreatic cancer pain.
• To test the hypothesis that OX is superior to MO in this patient population.
• To evaluate pain and symptom intensity, as well as opioid dose requirements.

Main Methods:

• A randomized study involving 60 patients with pancreatic cancer and moderate pain.
• Patients received either sustained-release oral morphine (30 mg/d) or oxycodone (20 mg/d).
• Opioid doses were adjusted based on clinical need, with assessments at baseline and up to 8 weeks.

Main Results:

• No significant differences were observed between oxycodone and morphine groups in terms of age, Karnofsky scores, or opioid escalation indexes.
• Pain and symptom intensity showed no statistical differences between the two treatment groups.
• Both oxycodone and morphine provided comparable analgesia and adverse effect profiles.

Conclusions:

• Oxycodone and morphine demonstrate similar efficacy and safety profiles for managing pancreatic cancer pain.
• The hypothesis that oxycodone would be superior to morphine in this context was not supported by the study findings.
• These results align with observations in the broader cancer pain population.